Sustained transgene expression in vitro and in vivo using an epstein-barr virus replicon vector system combined with HVJ liposomes

Gene Therapy

Volumn 5, Issue 8, 1998, Pages 1031-1037

  Saeki, Y ^a   Wataya Kaneda, M ^a   Tanaka, K ^a   Kaneda, Y ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

EBV vector; HVJ liposome; Long term gene expression

Indexed keywords

CATION; CELL NUCLEUS ANTIGEN; LIPOSOME; LUCIFERASE;

ANIMAL CELL; ARTICLE; CELL STRAIN BHK; CLONING VECTOR; DNA REPLICATION ORIGIN; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PARAINFLUENZA VIRUS 1; PLASMID; PRIORITY JOURNAL; REPLICON; TRANSGENE;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 4; HUMAN PARAINFLUENZA VIRUS 1; RODENTIA;

EID: 0031681367     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300711     Document Type: Article

References (32)

1. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
2. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
3. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-459.
4. Kotin RM et al. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992; 11: 5071-5078.
5. Wisokenski DA, Yates L. Multiple EBNA-1 binding sites are required to form an EBNA-1-dependent enhancer and to activate a minimal replication origin within oriP of Epstein-Barr virus. J Virol 1989; 63: 2657-2666.
6. Reisman D, Yates JL, Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol 1985; 5: 1822-1832.
7. Sugden B, Marsh K, Yates JL. A vector that replicates as a plasmid can be efficiently selected in B-lymphoblasts transformed by EBV. Mol Cell Biol 1985; 5: 410-413.
8. Robertson ES, Ooka T, Kieff ED. Epstein-Barr virus vector for gene delivery to B lymphocytes. Proc Natl Acad Sci USA 1996; 93: 11334-11340.
9. Wohlgemuth JG et al. Long-term gene expression from autonomously replicating vectors in mammalian cells. Gene Therapy 1996; 3: 506-512.
10. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA coin troduced with nuclear protein in adult rat liver. Science 1989; 243: 375-378.
11. Dzau VJ et al. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93: 11421-11425.
12. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
13. Calos MP. The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet 1996; 12: 463-466.
14. Saeki Y et al. Development and characterization of cationic lipo somes conjugated with HVJ (Sendai virus); reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8: 1965-1972.
15. Lupton S, Levme AJ Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein- Barr virus-derived plasmids in human cells. Mol Cell Biol 1985; 5: 2533-2542.
16. Jankelevich S et al. A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid in Raji cells into a single DNA domain. EMBO J 1992; 11: 1165-1176.
17. Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 1989; 63: 2644-2649.
18. Reisman D, Sugden B. Transactivation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr virus nuclear antigen 1, Mol Cell Biol 1986; 6: 3838-3846.
19. Banerjee S, Livanos E, Vos, JM. Therapeutic gene delivery in human B lymphoblastoid cells by engineered non transforming infectious Epstein-Barr virus. Nature Med 1995; 1: 1303-1308.
20. Harrington JJ et al. Formation of de novo centromeres and construction of first-generation human artificial microchromosomes. Nat Genet 1997; 15: 345-355.
21. Rosenfeld MA Human artificial chromosomes get real. Nat Genet 1997; 15: 333-335.
22. Hammerschmidt W, Sugden B Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 1989; 340: 393-397.
23. Mannick JB et al. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B lymphocyte transformation. J Virol 1991; 65: 6826-6837.
24. Tornkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B lymphocyte growth transformation. J Virol 1993; 67: 2014-2025.
25. Cohen JI et al. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 1989; 86: 9558-9562.
26. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B lymphocyte growth transformation. Proc Natl Acad Sci USA 1993; 90: 9150-9154.
27. Saeki Y, Kaneda Y. Protein modified liposomes (HVJ liposomes) for the delivery of genes, oligonucleotides and proteins. In: Celis JE (ed). Cell Biology: A Laboratory Handbook, 2nd edn. Academic Press: San Diego, 1998, pp 123-130.
28. Fregien N, Davidson N. Activation elements in the promoter region of the chicken β-actin gene. Gene 1986; 48: 1-11.
29. Mercer EH et al. The dopamine β-hydroxylase gene promotor directs expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron 1991; 7: 703-716.
30. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280-285.
31. Lanford RE et al. Effect of basic and nonbasic amino acid substitutions on transport induced by Simian, virus 40 T-antigen synthetic peptide nuclear transport signal. Mol Cell Biol 1988; 8: 2722-2729.
32. Hirt B. Selective extraction of polyoma DNA from infected mouse cell culture. J Mol Biol 1967; 26: 365-369.